Enlivex Announces Positive Interim Data From Early Stage Trial For Osteoarthritis Treatment

(RTTNews) - Enlivex Therapeutics Ltd. (ENLV), a clinical-stage macrophage reprogramming immunotherapy company, Monday announced positive interim six-month efficacy data from the Phase I stage of Allocetra trial in patients with moderate to severe knee osteoarthritis.

CEO Oren Hershkovitz said, "We are very excited about the 6-month interim results. The substantial and persistent pain reduction in these patients following AllocetraTM treatment is extremely important. We believe patients with moderate to severe knee osteoarthritis seek treatment offering an immediate, durable and marked improvement in their pain and function, and we believe these results, together with our previously reported Phase I interim results of patients measured three months following the administration of Allocetra injections, demonstrate the potential for Allocetra to be such a treatment."

"Our recruitment efforts for the Phase II stage of this trial are going according to plan, and we remain fully committed to assessing Allocetra's novel mechanism of action as a treatment alternative for patients with moderate to severe knee osteoarthritis," he added.

The multi-center Phase I/II clinical trial consists of two stages. The first stage, which was successfully completed, was a Phase I safety run-in, open-label dose escalation phase to characterize the safety and tolerability of Allocetra injections to the target knee in order to identify the dose and injection regimen for the subsequent Phase II stage described below.

The second stage is progressing along the previously announced timeline, and the Company currently expects a topline data readout from the Phase I/II trial by the third quarter of 2025.